The aim of the study was to evaluate the costeffectiveness of peginterferon alfa-2a (40KD) for the treatment of patients with HBeAg-negative chronic hepatitis B in Poland. The analysis compared two strategies: peginterferon alfa-2a (40KD) vs. lamivudine for 48 weeks (short-term analysis) or peginterferon alfa-2a (40KD) for 48 weeks vs. lamivudine for 4 years (long-term analysis). METHODS: The analysis was performed from the Polish payer perspective using a state-transition Markov model. Quality-adjusted life years (QALYs) was adopted as a measure of effectiveness. Efficacy with peginterferon alfa-2a (40KD) and lamivudine after 48 weeks of treatment was obtained from a randomized controlled trial (Marcellin et al. NEJM 2004;351(12):32-43). Long-term lamivudine efficacy, health state transition probabilities and utility estimates were obtained from the published literature. Direct medical costs, i.e. cost of drugs and procedures in the treatment of hepatitis B and its complications (cirrhosis, hepatocellular carcinoma, liver transplantation) were obtained from Polish sources. Costs and benefits were discounted at a 3% annual rate. RESULTS: Peginterferon alfa-2a 40(KD) vs. lamivudine for 48 weeks (short-term analysis) increased QALYs by 0,89. The mean treatment cost in the short-term analysis was 17,743 € (1€ = 4.035 PLN) and 12,522 € per patients for peginterferon alfa-2a and lamivudine, respectively. The incremental cost-effectiveness ratio (ICER) was 9316 €/QALY gained. In the long-term analysis, peginterferon alfa-2a (40KD) increased QALYs by 0,75. The mean cost of treatment was 17 €398 for peginterferon alfa-2a (40KD) and €13,890 for lamivudine per patient. The incremental cost-effectiveness ratio (ICER) was €7643 per QALY gained. CONCLUSIONS: The ICER for peginterferon alfa-2a evaluated in the short-term analysis as well as in the long-term analysis did not exceed €14,870 (cost of one year dialysis in Poland). Thus, the procedure appears to be costeffective in Poland. Amgen Europe, Zug, Switzerland, 4 Universitäts-Frauenklinik Frankfurt, Frankfurt, Germany OBJECTIVES: Primary (first and subsequent cycles) prophylaxis with filgrastim or pegfilgrastim has been recommended in 2006 clinical guidelines when the risk of febrile neutropenia (FN) is about 20%. Recent studies reported significantly greater reduction of FN with pegfilgrastim. In clinical practice, filgrastim has often been used for fewer than the recommended 11 days (e.g., 5-6 days), which has been shown to compromise the clinical outcomes. The study purpose was to evaluate the cost-effectiveness of pegfilgrastim vs. filgrastim (11-or 6-day) primary prophylaxis in women with breast cancer (stage I-III) receiving chemotherapy with moderate to high FN risk in Germany. METHODS: We constructed a decision-analytic model from a health care payer's perspective. Costs included drugs, drug administration, FNrelated hospitalizations and subsequent costs, and were based on Rote Liste (list price) and DRG Tariff. Effectiveness was measured as FN avoided and life-year-gained (LYG). FN risk (varied by days of filgrastim), FN case-fatality, relative dose intensity (RDI), and the impact of RDI on survival were based on a comprehensive literature review and expert panel validation. Breast cancer mortality and all-cause mortality were from official statistics. Sensitivity analyses were conducted on key variables. RESULTS: Pegfilgrastim use avoided more FN events, produced greater LYG and was less expensive than 11-day filgrastim. Compared with 6-day filgrastim, pegfilgrastim avoided 10.5 absolute percentage point of FN (17.5% vs. 7%) at a modest cost increase (€1306); the incremental cost-effectiveness ratio (ICER) was €12,429 per FN avoided. The average life expectancy was 15.99 years with pegfilgrastim and 15.88 years with filgrastim, yielding an ICER of €11,972/LYG. Age of diagnosis and cancer stage had minimal impact on the results. Drug costs and FN risk has moderate influence on model results. CONCLUSIONS: In Germany, pegfilgrastim appeared to dominate 11-day filgrastim and to be cost-effective within normal thresholds compared with 6-days filgrastim per cycle. Efficacy data were used from published clinical trial results. Lifeexpectancy was estimated by the DEALE method, using Swedish life tables. Utility values were obtained by standard gamble in a CHB health-utility study. Costs: 10-year treatment costs were estimated using drug acquisition costs published by the LFN. Costs of CC, DC, and HCC are from a Swedish costing study. Discounting: Both costs and outcomes were discounted at 3% annually. Sensitivity analyses were performed to various parameters. RESULTS: ETV therapy in nucleoside-naïve patients is a dominant treatment strategy compared to LVD therapy with ADV salvage. Cost savings of SEK 8,121,199/SEK 1,1902,137, QALYs gained 85.70/19.17 for HBeAg-positive/HBeAg-negative patients, respectively. Treatment with ETV is a dominant treatment strategy compared to ADV in LVD-refractory patients. Cost savings: SEK 3,612,483, QALYs gained 38.67. Across patient populations and comparators, ETV was associated with lower projections of liver-related events, a lower mortality rate
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Amgen Europe, Zug, Switzerland, 4 Universitäts-Frauenklinik Frankfurt, Frankfurt, Germany OBJECTIVES: Primary (first and subsequent cycles) prophylaxis with filgrastim or pegfilgrastim has been recommended in 2006 clinical guidelines when the risk of febrile neutropenia (FN) is about 20%. Recent studies reported significantly greater reduction of FN with pegfilgrastim. In clinical practice, filgrastim has often been used for fewer than the recommended 11 days (e.g., 5-6 days), which has been shown to compromise the clinical outcomes. The study purpose was to evaluate the cost-effectiveness of pegfilgrastim vs. filgrastim (11-or 6-day) primary prophylaxis in women with breast cancer (stage I-III) receiving chemotherapy with moderate to high FN risk in Germany. METHODS: We constructed a decision-analytic model from a health care payer's perspective. Costs included drugs, drug administration, FNrelated hospitalizations and subsequent costs, and were based on Rote Liste (list price) and DRG Tariff. Effectiveness was measured as FN avoided and life-year-gained (LYG). FN risk (varied by days of filgrastim), FN case-fatality, relative dose intensity (RDI), and the impact of RDI on survival were based on a comprehensive literature review and expert panel validation. Breast cancer mortality and all-cause mortality were from official statistics. Sensitivity analyses were conducted on key variables. RESULTS: Pegfilgrastim use avoided more FN events, produced greater LYG and was less expensive than 11-day filgrastim. Compared with 6-day filgrastim, pegfilgrastim avoided 10.5 absolute percentage point of FN (17.5% vs. 7%) at a modest cost increase (€1306); the incremental cost-effectiveness ratio (ICER) was €12,429 per FN avoided. The average life expectancy was 15.99 years with pegfilgrastim and 15.88 years with filgrastim, yielding an ICER of €11,972/LYG. Age of diagnosis and cancer stage had minimal impact on the results. Drug costs and FN risk has moderate influence on model results. CONCLUSIONS: In Germany, pegfilgrastim appeared to dominate 11-day filgrastim and to be cost-effective within normal thresholds compared with 6-days filgrastim per cycle. Efficacy data were used from published clinical trial results. Lifeexpectancy was estimated by the DEALE method, using Swedish life tables. Utility values were obtained by standard gamble in a CHB health-utility study. Costs: 10-year treatment costs were estimated using drug acquisition costs published by the LFN. Costs of CC, DC, and HCC are from a Swedish costing study. Discounting: Both costs and outcomes were discounted at 3% annually. Sensitivity analyses were performed to various parameters. RESULTS: ETV therapy in nucleoside-naïve patients is a dominant treatment strategy compared to LVD therapy with ADV salvage. University of Groningen/Groningen University Institute for Drug Exploration (GUIDE), Groningen, Groningen, The Netherlands OBJECTIVES: The risk of HIV, HBV and HCV transmission by blood transfusion in sub Saharan Africa is (very) high compared to the developed world. In this economic evaluation the costeffectiveness of interventions (donor management, quality of testing, administration and additional tests) improving blood transfusion safety is explored. METHODS: The residual risks of HIV, HBV and HCV transmission were derived for Angola, Benin, Botswana, Côte d'Ivoire, Ethiopia, Kenya, Mozambique, Namibia, Rwanda, Uganda and Zambia from the Global Database on Blood Safety (GDBS; WHO, 2004) . Cost-effectiveness ratios of the scenarios were determined by using a decision tree combined with a Markov-model. Health gains and costs were discounted by 3%. RESULTS: The CURRENT (current status) scenario is cost-saving compared to the NONE (no screening, no donor management) scenario, averting 2.0 million Disability Adjusted Life Years (DALYs) and saving US$ 82 million annually. Over 94,000 new HIV infections are averted and 27,674 and 3360 new HBV and HCV infections respectively. Improving the blood transfusion services from the CURRENT to the BEST (100% screening, no errors) scenario shows a cost-effectiveness ratio of 56.24 US$/DALY averted. With this step 2792 new HIV infections are averted and 1723 and 1622 new HBV and HCV infections respectively. In addition to the BEST scenario, HIV p24 and HCV-antigen testing would avert 19 DALYs at annual net costs of US$ 1.2 million (63,957 US$/DALY averted). Extending the BEST scenario with single donation multiplex NAT averts 60 DALYs at annual net costs of US$ 9.7 million (161,051 US$/DALY averted). CONCLUSIONS: The current level of blood transfusion safety provided in the included countries is cost-saving. However, maximizing the effects of donor management and screening (coverage and errors) shows a favorable cost-effectiveness ratio. Introducing additional tests alongside antibody testing is associated with high costs and limited reduction of transmission risks.
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